Interleukin-27 as a potential therapeutic target for rheumatoid arthritis: has the time come?

Clin Rheumatol. 2013 Oct;32(10):1425-8. doi: 10.1007/s10067-013-2341-0. Epub 2013 Jul 23.

Abstract

Interleukin (IL)-27 is a novel member of the IL-6/IL-12 family of cytokines with a broad range of pro- and anti-inflammatory properties. Recently, accumulating evidence has shown that IL-27 can play either a pathogenic or a protective role in animal models of inflammatory arthritis, depending upon the model and underlying pathogenic mechanisms. As to human system, elevated expression of IL-27 has clearly been detected in the synovial membranes and fluid from patients with rheumatoid arthritis (RA). Moreover, stimulation of IL-27 receptor with IL-27 of fibroblast-like synoviocytes from RA had a suppressive effect on the production of proinflammatory cytokines in vitro. All these findings suggest that IL-27 may have promise as a potential therapeutic target for RA. In this review, we will discuss the biological features of IL-27 and summarize recent advances on both pathogenic and protective roles of IL-27 in RA.

Publication types

  • Review

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / metabolism*
  • Arthritis, Rheumatoid / therapy*
  • Cytokines / metabolism
  • Disease Models, Animal
  • Fibroblasts / metabolism
  • Humans
  • Inflammation
  • Interleukin-27 / metabolism*
  • Mice
  • Receptors, Interleukin / metabolism
  • Signal Transduction
  • Synovial Fluid / cytology
  • Synovial Membrane / metabolism

Substances

  • Cytokines
  • IL27RA protein, human
  • Interleukin-27
  • Receptors, Interleukin